

CITATION REPORT

List of articles citing

Incidence and determinants of QT interval prolongation in COVID-19 patients treated with hydroxychloroquine and azithromycin

DOI: 10.1111/jce.14594

Journal of Cardiovascular Electrophysiology, 2020, 31, 1904-1

Source: <https://exaly.com/paper-pdf/76665793/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
28	Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis. <i>Journal of King Saud University - Science</i> , 2020 , 32, 3159-3166	3.6	9
27	Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. <i>Journal of Critical Care</i> , 2020 , 59, 176-190	4	44
26	Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106212	14.3	9
25	Where are we with understanding of COVID-19?. <i>Advances in Biological Regulation</i> , 2020 , 77, 100745	6.2	1
24	QT prolongation with hydroxychloroquine and azithromycin for the treatment of COVID-19: The need for pharmacogenetic insights. <i>Journal of Cardiovascular Electrophysiology</i> , 2020 , 31, 2793-2794	2.7	2
23	Azithromycin/hydroxychloroquine. <i>Reactions Weekly</i> , 2020 , 1819, 61-61	0	
22	Where are we with understanding of COVID-19?. <i>Advances in Biological Regulation</i> , 2020 , 78, 100738	6.2	3
21	Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021 , 46, 17-27	2.2	14
20	Hydroxychloroquine: Not a Heart Breaker!. <i>Arthritis Care and Research</i> , 2021 , 73, 770-771	4.7	
19	Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. <i>Clinical Toxicology</i> , 2021 , 59, 12-23	2.9	24
18	Patch monitors for arrhythmia monitoring in patients for suspected inherited arrhythmia syndrome. <i>Journal of Cardiovascular Electrophysiology</i> , 2021 , 32, 856-859	2.7	0
17	COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021 , 377, 265-272	4.7	7
16	QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 694-706	2.6	13
15	Effect of Hydroxychloroquine on QTc in Patients Diagnosed with COVID-19: A Systematic Review and Meta-Analysis. <i>Journal of Cardiovascular Development and Disease</i> , 2021 , 8,	4.2	
14	Medication safety in a pandemic: A multicentre point prevalence study of QTc monitoring of hydroxychloroquine for COVID-19. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021 , 46, 1308-1311	2.2	1
13	Azithromycin: Immunomodulatory and antiviral properties for SARS-CoV-2 infection. <i>European Journal of Pharmacology</i> , 2021 , 905, 174191	5.3	8
12	No difference in biomarkers of ischemic heart injury and heart failure in patients with COVID-19 who received treatment with chloroquine phosphate and those who did not. <i>PLoS ONE</i> , 2021 , 16, e0256035	2.7	35

11	Electrocardiographic manifestations of COVID-19: Effect on cardiac activation and repolarization. <i>EClinicalMedicine</i> , 2021 , 39, 101057	11.3	0
10	Comparing of the First Electrocardiographic Variables in Patients with Newly Diagnosed COVID-19 with Healthy Men Volunteer: A Systematic Review and Meta-Analysis. <i>Iranian Journal of Public Health</i> , 2021 , 50, 46-57	0.7	
9	Predictors of QT Interval Prolongation in Critically-ill Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine.		
8	Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association.. <i>Circulation</i> , 2022 , CIR00000000000001052	16.7	196
7	QT Prolongation in Critically Ill Patients With SARS-CoV-2 Infection.. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2022 , 27, 10742484211069479	2.6	
6	Hydroxychloroquine alone or in combination with azithromycin and corrected QT prolongation in COVID-19 patients: A systematic review. <i>World Journal of Meta-analysis</i> , 2021 , 9, 557-567	0.5	
5	Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review. <i>Pharmaceuticals</i> , 2022 , 15, 634	5.2	1
4	QTc Prolongation with the Use of Hydroxychloroquine and Concomitant Arrhythmogenic Medications: A Retrospective Study Using Electronic Health Records Data. <i>Drugs - Real World Outcomes</i> ,	2.2	
3	Treating Asthma in the Time of COVID. 2022 ,		0
2	Heart Disease and Stroke Statistics2023 Update: A Report From the American Heart Association.		9
1	Prospective QTc interval monitoring avoids cardiac toxicity of hydroxychloroquine and azithromycin in critically ill SARS-CoV-2 patients: a cohort study.		0